While the acute toxicity of RT is low, there has been increasing concern with regards to potential long-term radiation-induced morbidity, including impaired spermatogenesis, chronic gastrointestinal complications and second malignancy. These concerns, together with the availability of improved imaging techniques and more effective salvage treatment for relapse, have led to the exploration of alternative management approaches and reduction of the intensity of RT. However, it is important to ensure that these changes do not compromise the current excellent survival outcomes.
INTRODUCTION
Approximately 75% of patients with testicular seminoma present with Stage I disease. There are several management options for this stage of seminoma, including adjuvant radiotherapy (RT), surveillance or chemotherapy.The traditional management approach for Stage I pure seminoma has been radical inguinal orchidectomy followed by adjuvant external beam RT to the para-aortic and ipsilateral pelvic regions. With follow up consisting of clinical examination, serum tumour markers and chest X-ray (CXR), the long-term results are excellent with relapse-free rates of 94-98%. With the use of salvage chemotherapy, long-term survival approaches 100%. [1] [2] [3] While the acute toxicity of RT is low, there has been increasing concern with regards to potential long-term radiation-induced morbidity, including impaired spermatogenesis, chronic gastrointestinal complications and second malignancy. These concerns, together with the availability of improved imaging techniques and more effective salvage treatment for relapse, have led to the exploration of alternative management approaches and reduction of the intensity of RT. However, it is important to ensure that these changes do not compromise the current excellent survival outcomes.
A recent pooled analysis of four surveillance series comprising 638 patients, with a median follow up of 7 years, has reported a relapse rate of 18%. 4 The majority of recurrences (85-90%) are limited to the para-aortic lymph nodes, and are successfully salvaged by RT. Although most first recurrences occur within 2 years of orchidectomy, recurrences have been
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reported as late as 9 years from diagnosis. [5] [6] [7] Thus, surveillance, which requires intensive follow up over a long period, depends upon both a motivated clinician and a compliant patient. Given these caveats, surveillance is a viable therapeutic alternative as it appears to provide a survival rate equivalent to that achieved with standard adjuvant RT.
Refinements to reduce the morbidity of RT have included reduction of the target volume. The Medical Research Council (MRC) trial comparing para-aortic and ipsilateral pelvic radiation or 'dog-leg' (DL) to a para-aortic strip alone (PA) in 478 patients reported no difference in disease-free or overall survival between the two arms. 8 The acute toxicity, specifically haematologic, gonadal and gastrointestinal, was reduced in the PA arm. There were nine relapses in each arm, with four of those in the PA arm located in the pelvis. This was an equivalence trial, powered to detect a difference in pelvic relapse of greater than 3%, and thus, small differences in outcomes might not have been detected. 
METHODS AND MATERIALS
A survey was conducted between March and April 2001. 
RESULTS
Seventy-four questionnaires were returned by the end of April.
All responders were practicing radiation oncologists based in Australia, New Zealand and Singapore.
Radiological investigations
One 
Management options
Just over half (54%) of the respondents stated that they offered their patients the option of surveillance. Among those offering surveillance, they estimated that 5% or less (range 0-30%) of the patients in their practice would choose this option (Table 1) .
Radiation oncologists were asked to rank, in order of preference, three management options in the presence or absence of concern about fertility. The three management options were:
(i) surveillance with reservation of RT or chemotherapy for relapse; (ii) postoperative adjuvant RT using either PA or DL field;
and (iii) postoperative adjuvant single-agent chemotherapy.
In patients for whom fertility was a specific concern, 80% of radiation oncologists indicated that adjuvant radiotherapy would be their preferred management for that patient. In the absence of this concern, this increased to 96%. Many of the replies did specifically state that sperm banking would be organized prior to RT if necessary. There was a corresponding reduction in the proportion of clinicians favouring surveillance as the preferred option for the two scenarios, falling from 18 to 3%. Two radiation oncologists replied that they would favour adjuvant chemotherapy in the situation where fertility was an issue for the patient and in the absence of a fertility concern, this reduced to one.
Adjuvant radiotherapy
Seventy-five percent of Australasian radiation oncologists elected a para-aortic field alone as their treatment volume.
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Thirty-four percent used a dog-leg and one described their volume as an 'amputated dog-leg', which treated the para-aortic and ipsilateral common iliac nodes. For the question regarding dose-fractionation schedules, this latter volume was included as a DL field. (Table 2) .
Forty-two of 48 radiation oncologists had changed their treatment volume after the publication in 1999 of the MRC trial comparing para-aortic with para-aortic plus ipsilateral pelvic fields. Six had already been using the smaller volume and were regarded as not being influenced by this trial.
Those clinicians treating their patients with PA RT were asked to state the frequency of CT scanning to monitor the pelvis. As per Table 3 , most (40%) performed annual CT scans, 23% performed them every 6 months and 15 (31%) did none. Seventy-nine and 75% of Canadian and US respondents, respectively, stated that they would routinely recommend surveillance as a management option. When the option of surveillance was raised, the median estimated proportion of patients choosing it was 20% in Canada (range 0-100) and 7.5% in the US (range 0-50).
North American results
Seventy
In Canada, the DL was more prevalent than the PA field (55 vs 42%), whereas in the USA, 54% used the PA field. Two North American radiation oncologists routinely used a 'modified dog-leg' that targeted the para-aortic and ipsilateral commmon iliac regions.
The most frequently used dose-fractionation schedule in Twenty-six percent of Canadians utilizing PA RT reported that they reduced their treatment volume from a dog-leg to paraaortic as a result of the MRC study whereas 38% did so in the USA.
Of those radiation oncologists using the PA field, 41 and 50% would perform a CT scan annually and every 6 months, respectively, for 3 years in order to monitor the pelvis. Only 9% did no follow-up CT scan. As parts of the questionnaire are identical to a survey conducted in Canada and the USA during a similar period, certain practices can be compared and contrasted. However, it must be noted that the groups targeted in these three areas differed markedly. The Canadian Association of Radiation Oncologists has information on subsite specialization; therefore, If yes, what proportion of your patients opt for the surveillance? 14 = 0%, 4 = no response, 7 = 10%, 5 = 5%, 3 < 10%, 3 < 5%, 1 = 20%, 1 = 30%, 2 = 1%. Median 5%, range 0-30%. all radiation oncologists treating genitourinary tumours could be identified, and by contacting individual provincial regional cancer centres, included in the survey. The survey was very selectively targeted in the USA where it was distributed only to the RTOG genitourinary committee members. By contrast, the survey distributed by the RANZCR might be over-inclusive as it targeted all practicing radiation oncologists affiliated with the College. Hence, the Australasian survey should be regarded as a study of management preferences rather than a definitive assessment of patterns of practice. At the opposite end of the spectrum, the US results reflect academic rather than community practice in that country. Finally, for a more comprehensive view, it might be important to include urologists and medical oncologists in future studies as they are involved in the patterns of referral and care of these patients.
DISCUSSION
Radiological investigations
With the exception of one radiation oncologist who did not The latter has been evaluated in two studies. 12, 13 In both, surveillance was more expensive than adjuvant dog-leg RT.
Neither study incorporated the dollar cost of second malignancies into their calculations as this data is as yet unavailable for the surveillance series.
There was no significant difference in the proportion of radiation oncologists offering the option of surveillance between Canada and the USA. Both were more likely to offer surveillance than members of the RANZCR. However, when asked to estimate the proportion of patients choosing surveillance in their practice, there was a marked difference between the two countries. In Canada, radiation oncologists estimated that a median of 20% would opt for surveillance, whereas this estimate was only 7.5% in the USA, perhaps reflecting the fact that the Princess Margaret Hospital in Toronto, Canada, routinely offers the option of surveillance, and has a large experience with this approach. Locally, only ≤5% of patients were estimated to opt for surveillance, and just over half (54%) of the clinicians stated that they routinely offered this option.
When a patient had specific fertility concerns, 80% of radiation oncologists indicated that adjuvant RT would be their 3 years after RT in both arms. In the discussion section of the MRC paper, it was suggested that CT scanning every 6 months might be preferred for earlier detection of relapse as there were four pelvic relapses in the PA group. However, only two were isolated pelvic relapses, so the yield from scanning is very low. Philosophically, PA RT involves treating the most likely anatomical area of relapse with observation of the pelvis.
Furthermore, the exact location of the four pelvic relapses (of which two were isolated) in the PA arm of the MRC trial were not given. If, for example, all the pelvic recurrences occurred in the common iliac lymph nodes, this raises the possibility that the optimal treatment field might in fact extend from T11 to the lower sacroiliac joints. Such a field would be associated with less acute toxicity than a DL, but might be associated with an even lower risk of pelvic relapse than PA alone, obviating the need for pelvic surveillance. 
CONCLUSION
There has been a trend towards using a smaller RT volume, strongly influenced by the published MRC trial. However, there is little consensus with respect to pelvic follow up after PA irradiation. Although 54% of radiation oncologists discuss the option of surveillance, few patients select this option.
Compared to North America, we are more likely to use PA fields and less likely to discuss surveillance as an option.
A minority of our patients will opt for surveillance where this management alternative is discussed with the patient. Finally, although North American radiation oncologists are more likely than Australasians to perform CT scans of the pelvis after PA treatment, there is no consensus regarding the frequency of these scans in any of these countries.
